Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited announce that the first participant, based in the United States, was dosed in a global Phase I trial of IMG-004, a non-covalent, reversible, third-generation Bruton Tyrosine Kinase ("BTK") inhibitor. Inmagene is developing the drug candidate to potentially treat immunological diseases. The Phase I study is a double-blind, randomized, placebo-controlled, single and multiple dose escalation study in healthy subjects.

The study aims to explore IMG-004's safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects. Additional details can be found at clinicaltrials.gov, using identifier NCT05349097. IMG-004 is a non-covalent, reversible small molecule inhibitor targeting BTK.

Designed specifically for inflammatory and autoimmune diseases that usually require long-term treatment, IMG-004 is potent, highly selective and brain permeable. It was originally discovered by HUTCHMED, with Inmagene assuming development responsibility at the candidate stage. Inmagene has an exclusive option to in-license IMG-004's global rights for the treatment of immunological diseases.